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Abstract N-Glycosylation is a common post-translational
modification of monoclonal antibodies with a potential ef-
fect on the efficacy and safety of the drugs; detailed knowl-
edge about this glycosylation is therefore crucial. We have
developed a reversed-phase liquid chromatographic–mass
spectrometric method, with different fluorescent labels, for
analysis of N-glycosylation, and compared the sensitivity
and selectivity of the methods. Our work demonstrates that
anthranilic acid as fluorescent label in combination with
reversed-phase liquid chromatography–mass spectrometry
is an advantageous method for identification and quantifi-
cation of neutral and acidic N-glycans. Our results show that
mass spectrometry-based quantification correlates with
quantification by fluorescence. Chromatographic discrimi-
nation between several structural glycan isomers was
achieved. The sharp peaks of the eluting anthranilic acid-
labeled N-glycans enabled on-line mass spectrometric anal-
ysis of even low-abundance glycan species. The method is
broadly applicable to N-glycan analysis and is an orthogonal
analytical method to the widely established hydrophilic-
interaction liquid chromatography of 2-aminobenzamide-
labeled N-glycans for characterization of N-glycans derived
from biopharmaceuticals.
Keywords Anthranilic acid . 2-aminobenzamide . Mass
spectrometry .N-glycosylation . Reversed-phase











HILIC Hydrophilic interaction liquid chromatography
HPLC High-performance liquid chromatography
LC Liquid chromatography
mAb Monoclonal antibody
MALDI Matrix-assisted laser desorption ionization
MS Mass spectrometry
PNGaseF Peptide N-glycosidase F
PGC Porous graphitized carbon
RP Reversed phase
Introduction
Recombinant protein drugs belong to the most complex active
pharmaceutical ingredients. Monoclonal antibodies (mAbs),
glycoproteins with a molecular mass of approximately
150 kDa are one important class. Glycosylation has attracted
interest because many investigations have shown that such
modification may have an effect on the safety and efficacy of
these therapeutic protein drugs [1–5]. In general, IgGs have one
conserved N-glycosylation site on each heavy chain at their Fc
part, usually at approximate position 297 of the heavy chain,
and several mAbs carry a second N-glycosylation site in their
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variable region. The heterogeneity of the N-glycans attached to
these sites is very high, far more than a dozen different glycans
can be found [6]. Identification and quantification of the gly-
cans in this mixture is difficult, and structural isomers of several
glycans make discrimination even more challenging [7–9]. A
comprehensive analytical approach is therefore required. N-
Glycosylation can be studied, after enzymatic release of the
glycans by use of peptide N-glycosidase F (PNGaseF), by
liquid chromatography, mass spectrometry (MS) [10], or a
combination of these [9–14]. Structural analysis of underivat-
ized or labeled N-glycans is usually performed byMALDI-MS
or by use of porous graphitized carbon (PGC) liquid chroma-
tography in combination with on-line ESI MS2 [15–17].
Underivatized N-glycans have no light-absorbing proper-
ties. They can be derivatized with a fluorophore [18] for
quantitative analysis by HPLC. Labeling with a fluorescent
dye via reductive amination is widely used [12, 18]. This
derivatization results in high sensitivity and, because every
N-glycan carries only one label, irrespective of size or branch-
ing, quantitative information can be obtained from the inten-
sity of the fluorescence signal. The tag not only enables UVor
fluorescence detection—it also improves ionization and frag-
mentation of the labeled N-glycan in ESI–MS [19, 20].
For characterization ofN-glycans derived from biopharma-
ceuticals, 2-aminobenzamide (2-AB) is routinely used as label
[19, 21, 22], typically with separation and quantification by
HILIC (hydrophilic interaction liquid chromatography) with
fluorescence detection [23]. HILIC results in high resolution
and selectivity for many glycan isomers [24]. However, the
small injection volume of aqueous samples necessary, solvent
conditions that are essential because of the solubility of the
glycans, leads to reduced sensitivity in on-line MS detection,
and the buffered mobile phase may lead to ion suppression.
In contrast with this, the mobile phases used for RP HPLC
usually consist only of water, an organic solvent, and an acid;
they are, therefore, highlyMS-compatible. In addition, there are
almost no limitations with regard to injection volumes of aque-
ous solutions, which results in high sensitivity. It has been
shown that RP LC–MS of 2-AB or ANTS-derivatized oligo-
saccharides can be performed and used to characterize the N-
glycosylation pattern of mAbs [13, 14, 25, 26]. However, 2-AB
as fluorescent tag adds only weak hydrophobicity to the hydro-
philic glycan, which necessitates use of a shallow and long
chromatography gradient. Furthermore, labeled acidic glycans
elute early and are poorly separated [13]. This limitation was
solved by Melmer et al. [24] by addition of an ion-pairing
reagent. However, use of an ion-pairing reagent again leads to
ion suppression and thus reduced MS sensitivity. For analysis
of negatively charged N-glycans containing sialic acids, label-
ing with a negatively charged tag, for example 2-aminobenzoic
acid (2-AA) or 8-aminonaphthalene-1,3,6-trisulfonic acid
(ANTS) and MS detection in negative-ionization mode is fre-
quently used [14, 27–29]. Prien et al. separated oligomannose
structures (especially mannose 5 isomers) by RP LC after 2-AA
derivatization and analyzed them by use of MS in negative
mode [28]. The ability to separate complex N-glycan mixtures
or isomers, for example G1F N-glycans with either 1,3 or 1,6
galactosylation, highly abundant in most mAbs, has not been
reported for any N-glycan RP LC approach.
To provide solutions for the above mentioned limitations of
current N-glycan analytical methods we have developed and
optimized an RP LC–MS method with positive ionization for
characterization of complex N-glycosylation profiles. The
method was designed to characterize acidic and neutral N-
glycans in a single LC–MS approach. We compared the
sensitivity and selectivity of 2-AB and 2-AA as fluorescent
labels and showed that our newly developed 2-AA RP LC–
MS method has advantageous sensitivity and selectivity for a
variety of structural isomers analysis of which has not yet been
reported in the literature. By comparing results from quanti-
tative MS and from FLD we also demonstrated that quantifi-
cation of mAb glycans by these methods leads to very similar
results. The method is versatile and can be used to address
various questions in glycobiology or glycomics, from basic
screening of N-glycan composition, because of grouping of
the N-glycan types, to detailed analysis of low-abundance
glycan species. Furthermore our results show that even com-
plex and highly sialylated N-glycans can be investigated. This
flexibility and versatility make the method broadly applicable
to analysis of N-glycans and it can be applied with little effort
to analysis of many (glyco)proteins, or in proteomics and/or
glycomics laboratories, because the combination of RP LC
and MS is a routine application in such laboratories.
Materials and methods
Materials
PNGase F was from New England Biolabs (Frankfurt am Main,
Germany). Acetonitrile (ACN) and acetic acid were fromMerck
(Darmstadt, Germany). Formic acid, DMSO, and sodium cyano-
borohydride were from Fluka (Sigma, Munich, Germany).
Sephadex G-10 columns were custom made by GE Healthcare
(Vienna, Austria). Amicon Ultra 30-K filter devices were from
Millipore (Schwalbach, Germany). The mAb glycan standard
was prepared at Sandoz. Monoclonal antibodies 1–3 were
obtained from in-house development at Sandoz. The acidic N-
glycan standardswere fromThera Proteins (Barcarena, Portugal).
Methods
Enzymatic N-glycan release by use of PNGaseF
Desalted mAb (1 mg) was used. The N-glycans (15 nmol)
were released by incubating the samples with PNGaseF
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overnight (~17 h) at 37 °C. The N-glycans were separated
from the proteins by use of Amicon 30K filter devices and
were brought to dryness by use of a Speedvac.
Fluorescence labeling of released N-glycans or N-glycan
standards
Na[BH3(CN)] and either 2-AA or 2-AB were dissolved in
70:30 (%, v/v) DMSO–acetic acid to furnish concentrations
of 63 and 50 mgmL−1, respectively. Labeling solution
(15 μL) and deionized water (10 μL) were added either to
15 nmol enzymatically released and dried glycans or to 250
pmol lyophilized N-glycan standard. The labeling reaction
was performed at 37 °C for 17 h.
Excess label was removed by gel filtration on G-10
columns. Columns were conditioned with 10 mL H2O.
Samples were diluted to 100 μL with deionized water then
applied to the column. After rinsing the column with 700 μL
H2O the purified fluorescence-labeled N-glycans were
eluted with 600 μL H2O.
Reversed-phase HPLC of labeled N-glycans
Liquid chromatography was performed with an Agilent
1200 series chromatograph on a Waters Acquity UPLC
BEH130 C18 (2.1 mm×150 mm, 1.7-μm particle) column.
Analysis of 2-AA-labeled glycans was performed with a
gradient prepared from 1.0 % formic acid in H2O (component
A) and 50 % ACN in 1.0 % formic acid in H2O (component
B). The columnwas equilibrated with 4%B. After injection of
up to 100 μL sample themobile phase composition was held at
4 % B for 2 min. The proportion of B was then raised in four
steps to 28 %, first to 10 % over 27 min, then to 11.5 % over
10 min, then to 14 % over 8 min, and finally to 28 % over
19 min. The column was regenerated by increasing to 90 % B
over 4 min, followed by isocratic elution for 2 min. The
column was then re-equilibrated at 8 % B for 5 min.
Oven temperature was 50 °C and the flow-rate was
0.30 mLmin−1. Fluorescence detection was performed
with an excitation wavelength of 250 nm and an emis-
sion wavelength of 425 nm.
Analysis of 2-AB-labeled glycans was performed with a
gradient prepared from 0.5 % formic acid in H2O (compo-
nent A) and 0.5 % formic acid and 5 % ACN in H2O
(component B). The column was equilibrated with 25 %
B. After injection the mobile phase was held at 25 % B for
2 min. The proportion of B was then increased to 55 % over
60 min and then to 61 % over 24 min. This composition was
held for 2 min then the initial conditions were restored in
2 min and held for an additional 5 min. Oven temperature
was 40 °C and the flow rate was 0.3 mLmin−1. Fluorescence
detection was performed with an excitation wavelength of
250 nm and an emission wavelength of 428 nm.
Mass spectrometry
The HPLC was directly coupled to a 3D ion trap ESI–MS
(Bruker AmaZon). The ion trap was operated in enhanced
resolution mode with a capillary potential of 4 kV. The
capillary temperature was set to 250 °C with a nebulizer
pressure of 2 bar and a dry gas flow of 6 Lmin−1. MS2
spectra were generated by use of the Auto MS2 mode and
collision induced dissociation (CID).
Results and discussion
LC–MS of 2-AB-labeled N-glycans
Our RP LC–MS method entails use of two structurally
closely similar chemical labels, 2-AB and 2-AA. In a first
step an RP LC–MS method for 2-AB-labeled N-glycans was
developed. Because 2-AB-labeled N-glycans are weakly
retained on C18 columns, a mobile phase gradient with a
low organic solvent content was used. The separation was
optimum under the mobile phase conditions described in the
section “Reversed-phase HPLC of labeled N-glycans”. A
fluorescence chromatogram obtained from the 2-AB RP
LC–MS method for the mAb glycan standard is shown in
Fig. 1. The glycans elute in groups. To reduce the run time the
mobile phase composition was adapted. Use of formic acid
instead of acetic acid improved retention and led to sharper
peaks. A run time of 95 min was sufficient for analysis of the
N-glycans of an mAb. A shorter gradient and the resulting
reduction of run time led to loss of resolution, because of the
low hydrophobicity of the labeled N-glycans.
The first compounds eluting between 16 and 30 min from
the column are the high-mannose glycans, in the order high to
low number of mannose residues (Fig. 1, green). The acidic
hybrid and complex glycans (Fig. 1, pink) overlap with the
oligomannose group from approximately 22–26 min. The
next glycans to elute are the hybrid N-glycans lacking the
core fucose at the terminal GlcNAc (Fig. 1, orange), eluting
from 28–36 min. The complex bi-antennary 2-AB glycans
elute in the middle of the chromatogram (Fig. 1, blue, 42–
48 min) immediately before the acidic hybrid glycans with
core fucose. Hybrid (Fig. 1, orange, 57–71 min) and acidic
complex (Fig. 1, pink, 48–66 min) 2-AB glycans, both groups
with a fucose residue attached to their core, co-elute. The
group with the most abundant glycans in most mABs, the
complex type glycans with core fucose, elute at the end of the
chromatogram with retention times of 74–88 min. Sialic acid-
containing 2-AB-labeled glycans elute as sharp peaks before
their corresponding neutral glycans Fig. 2.
Labeled oligomannose and hybrid structures elute from high
to low number of monosaccharides whereas complex type 2-
AB glycans, including the acidic variants, elute from low to
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high number of monosaccharide units. Several 2-AB glycans
elute with similar retention times and could not be separated.
The 2-AB-labeled glycans were identified by MS and MS2 by
use of the ion-trap mass spectrometer. Table 1 contains the MS
data for the identified glycans, and the respective glycan struc-
tures are drawn in Fig. 3, with the appropriate nomenclature.
Fig. 1 (A) Fluorescence chromatogram obtained from separation of 2-
ABN-glycans on a RP column. The magnified view (B) of the chromato-
gram shows the smaller peaks of less abundant N-glycans. The numbered
peaks were identified by use of MS and MS2. Stacked numbering indi-
cates co-elution ofN-glycans. MS data of the identified peaks are listed in
Table 1. The 2-AB glycans elute in different groups depending on their
type. Oligomannose (green) glycans elute first, followed by acidic hybrid
and complex type (pink) and neutral hybrid glycans (orange). Acidic
hybrid with core fucose (pink) elute after complex glycans (blue). Neutral
hybrid structures (orange) co-elute between approximately 57 and
86 min, with acidic complexes followed by complex 2-AB glycans
(blue), with all three groups carrying a core fucose
Fig. 2 RP chromatogram
obtained from the mAb glycan
standard showing the grouping
of the eluting 2-AA N-glycans.
(A) High-mannose structures
elute first (green), followed by
non-fucosylated hybrid (orange)
and complex glycans (blue).
Fucosylated hybrid (orange) and
complex structures (blue) elute
last in the chromatogram. Acidic
glycans elute immediately before
their appropriate neutral glycans
(pink). (B) Magnified view of the
region between 18 and 42 min
showing the less abundant gly-
cans. The identified glycans are
numbered and the appropriate
masses are listed in Table 1.
Stacked numbering indicates co-
elution of N-glycans. The glycan
structures are depicted in Fig. 3
2484 F. Higel et al.
Separation of 2-AA-labeled N-glycans
As an alternative to 2-AB-labeled glycans, 2-AA-labeled
glycans were also tested using the developed 2-AB
method. Most 2-AA glycans remained on the column
after the 95-min gradient, only the oligomannose
structures eluted late. Because of this stronger retention
of the 2-AA-labeled glycans the mobile phase had to be
adapted to enable optimum separation. In contrast with
2-AB, 2-AA is negatively charged at neutral pH. Mobile
phase pH was therefore reduced to provide sufficient
protons for efficient ionization in positive MS mode.
Table 1 2-AA and 2-AB-labeled
glycans from mAb glycan stan-
dard identified by ion-trap MS
and MS2. Observed and theoreti-
cal mass are shown for each
assigned glycan. For N-glycan
isomers only one mass is shown.
The peak numbers correspond to
the appropriate peak numbering
in the chromatograms and to the
structures in Fig. 3
Peak 2-AA Glycans 2-AB Glycans N-Glycan
Observed mass Theoretical mass Observed mass Theoretical mass
5 1841.602 1841.645 1840.689 1840.661 M8
6, 7, 8, 9 1679.541 1679.592 1678.604 1678.608 M7
10 1031.406 1031.381 1030.425 1030.397 M3
11 1234.470 1234.460 1233.489 1233.476 M3G0
12 2027.716 2027.709 2026.739 2026.725 SM5G1
13, 14 1517.592 1517.539 1516.573 1516.555 M6
15 1396.550 1396.513 1395.54 1395.529 M3G1
16 1855.655 1865.656 1865.678 1864.672 SM4G1
17, 18, 19 1703.619 1703.603 1702.615 1702.619 SM3G1
20, 21 1193.457 1193.433 1192.49 1192.449 M4
22 1355.525 1355.486 1354.533 1354.502 M5
23, 24 1558.617 1558.566 1557.582 1557.582 M5G0
25 1720.647 1720.618 1719.643 1719.634 M5G1
26, 27, 28, 29 1599.618 1599.592 1598.612 1598.608 G1
30 1720.647 1720.618 1719.643 1719.634 M6G0
31 1558.592 1558.566 1557.576 1557.582 M4G1
32, 33 1437.586 1437.539 1436.565 1436.555 G0
34 1687.579 1687.608 – 1686.624 SM3G1
35, 36 1786.675 1786.677 1785.708 1785.693 G0F + GN
37 1583.710 1583.597 1582.648 1582.613 G0F
38 2173.726 2173.767 2172.78 2172.783 SM5G1F
39 2011.693 2011.714 2010.754 2010.73 SM4G1F
40 2376.763 2376.846 2375.787 2375.862 SG3F
41 1849.705 1849.661 1848.692 1848.677 SM3G1F
42, 43 2214.754 2214.793 2213.818 2213.809 SG2F
44, 45 2052.732 2052.740 2051.768 2051.756 SG1F
46 1948.741 1948.729 1947.804 1947.745 G1F + NG
47 2028.702 2028.729 – 2027.745 M6G1F
48, 49 1907.689 1907.703 1906.775 1906.719 G2F
50 1866.679 1866.676 1865.698 1865.692 M5G1F
51, 52 1704.609 1704.624 1703.644 1703.64 M5G0F
53 1866.650 1866.676 1865.668 1865.692 M6G0F
54 1583.533 1583.597 1582.608 1582.613 M3G0F + NG
55 1704.609 1704.624 1703.643 1703.64 M4G1F
56, 57 1542.566 1542.571 1541.582 1541.587 M3G1F
58 2069.748 2069.756 – 2068.772 G3F
59 1380.553 1380.518 1379.569 1379.534 M3G0F
60 1907.690 1907.703 1906.746 1906.719 G2F
61, 62 1745.610 1745.650 1745.655 1744.666 G1F
63 1583.709 1583.597 1582.607 1582.613 G0F
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Use of 1 % formic acid and an ACN content of com-
ponent B increased by a factor of 10 compared with the
2-AB method, to 50 %, enabled optimum separation and
good ionization. Higher signal intensity was observed
with positive-ionization MS compared with negative-
ionization mode. The resulting run-time was 78 min.
As observed for the 2-AB method a shorter gradient
resulted in substantial loss of resolution.
Figure 2 shows a fluorescence chromatogram
obtained from the 2-AA-labeled mAb glycan standard;
it is similar to that from the 2-AB method (Fig. 1). The
labeled glycans elute in different groups, highlighted
with different colors in Fig. 2. High-mannose structures
are the first group eluting from high number to small
number of monosaccharide residues, for example from
M9 to M5 (green, 19–27 min). Sialic acid containing
non-fucosylated hybrid and complex variants (pink, 23–
30 min) are then followed by the neutral non-
fucosylated hybrid variants (orange, 28–31 min). Com-
plex structures lacking the core fucose (blue, 30–
34 min) elute before sialic acid-containing hybrid
glycoforms and sialic acid-containing complex forms
(pink, 34–40 min), both with core fucosylation. Bisect-
ing structures co-elute with the latter. Neutral core-
fucosylated hybrid glycans (orange, 39–42 min) elute
before the most abundant core fucosylated complex
variants in mAbs, the bi-antennary N-glycans (blue,
42–51 min). This grouping is similar to that of our 2-
AB approach and to those of previous investigations
[13]. Sialic acid-containing non-fucosylated hybrid and
complex variants elute after the high-mannose and be-
fore the neutral non-fucosylated hybrid group. The same
order is observed for the core fucosylated hybrid and
complex glycoforms. Again, the same sharp peak shape
was obtained for the eluting sialic acid-containing 2-AA
glycans as for neutral glycans, without the need for an
ion-pairing reagent. Compared with the 2-AB method,
the peaks were sharper (e.g. the peak width of peak 63
is 0.72 min (2-AB) compared with 0.25 min (2-AA))
and more condensed. Because of the greater number of
separated glycan structures more partially resolved peaks
are present in the chromatogram.
Fig. 3 Symbol structures of the identified N-glycans. Numbering is in
accordance with the peak numbering for the N-glycans in the
fluorescence chromatograms and in Table 1. For structures with
multiple peak assignments only one possible isomer is drawn.
Symbols: inverted red triangles, L-fucose; blue squares, N-ace-
tyl-D-glucosamine; green circles, D-mannose; yellow circles, D-
galactose; blue diamonds, N-glycoylneuraminic acid; purple dia-
monds, N-acetyl-neuraminic acid
2486 F. Higel et al.
Identification of N-glycans by use of positive mode ESI–MS
and MS2
So far, 2-AA has been used almost exclusively with negative-
ionization MS [19, 20], because of the negative charge of the
acid group. The acidic mobile phase used in this investigation
favors proton adducts and resulted in good ionization efficien-
cy in positive-ionization mode. We observed higher signal
intensities for positive ionization than for negative ionization.
The high formic acid content of the mobile phase also led to
formation of formic acid clusters. 2-AA N-glycans were iden-
tified from their mass derived from mass spectra and from the
mass of appropriate fragments generated by CID. All 2-AB
and 2-AA N-glycans identified in the mAb glycan standard,
with their observed and calculatedmasses, are listed inTable 1.
Some glycan structures occur several times in course of the
chromatogram. These may be structural isomers or bisecting
or tri-antennary variants with the same mass that cannot be
distinguished because no linkage information is obtained by
use of this LC–MS approach.
The charge states of the labeled glycans increase with
increasing mass. Glycans with a mass<1200 Da occur almost
exclusively as [M + H]1+ ions, whereas glycans with
mass >1200 Da are doubly charged [M + 2H]2+; singly charged
[M +H]1+ ions, also, are present for glycans of mass <1500 Da.
For masses >1800 Da, the N-glycans begin to ionize as triply
charged [M + 3H]3+ ions, with the exception of oligomannose-
type glycans which usually furnish doubly charged ions. Ad-
duct ions are present for all charge states and the oligomannose
glycans tend to have the highest affinity for adduct formation.
Doubly and triply charged ions occur as mixed adducts also.
[M + Na]1+, [M + K]1+, [M + H + Na]2+, [M + 2Na]2+, and
[M + H + K]2+ are the most abundant adduct ions. On-line MS
detection provides more information than is required for iden-
tification of N-glycans solely on the basis of their mass and
fragments, because co-eluting 2-AA N-glycans can be identi-
fied and quantified by use of the extracted ion chromatograms
(EICs) of the appropriate m/z values. Figures 4 and 5 show the
MS2 spectra obtained after fragmentation of different N-glyco-
ylneuraminic acid-containing 2-AA glycans. The fragments
were labeled in accordance with the nomenclature of Domon
and Costello [30]. The spectra were acquired on-line by use of
positive ionization ESI–MS and CID fragmentation. Each of
the SG1F 2-AA glycan fragments (Fig. 4) can be explained by
the dissociation of a single bond, as expected from use of CID
in ion-traps. The MS2 spectrum at m/z 1027.9 is dominated by
B and Y ions. The fragmentation pattern of the sialic acid-
containing SM5G1F (Fig. 5) is slightly different. In the MS2
spectrum of the [M + 2H]2+ ion at m/z 1088.4 only B ions are
observed derived from the GlcNAc-containing branch, but not
from the mannose containing-branch of the hybrid struc-
ture. The fragments B3α and Y6α with m/z 528 and 366,
respectively, can be explained by loss of the terminal
sialylation. Figure 6 shows the MS2 spectrum at m/z
1035.9 of the rare G3F glycan, which accounts for less
than 0.01 % of the glycans. B ions are observed for
both branches of the glycan, because both contain a
GlcNAc. This 2-AA glycan co-elutes with the two over-
lapping and more abundant M3G0F and G2F peaks, but
it can be identified and quantified by use of on-line MS
detection. To check the performance of the method for more
complex sialic acid glycans we labeled and analyzed six acidic
glycan standards (Fig. 8 and also the section “Selectivity of
the two approaches”). The bi-antennary glycans ionized as
described above. For the tri and the tetra-antennary glycans we






















































Fig. 4 MS2 spectrum of the 2-
AA-labeled SG1F glycan from
mAb3 at m/z 1027.9. The dis-
sociated bonds of the [M +
2H]2+ ion are depicted and the
assigned B and Y ions are la-
beled in the spectrum. Dissoci-
ation of two bonds is indicated
by a slash
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terminal sialic acids was minimal and we observed almost no
in-source fragmentation. Only loss of an antenna was moni-
tored for the tetra-antennary N-glycan.
Selectivity of the two approaches
As mentioned in the “Introduction”, the complexity of gly-
cosylation is not only because of the multitude of different
N-glycan variants with different monosaccharide composi-
tion. It is also because of the existence of structural isomers
with different linkage types. To obtain a glycan-map as
comprehensive as possible it is important to separate
these isomers. Separation of oligomannose isomers, for
example, has been investigated and is described in sev-
eral publications [6, 9, 27].
Figure 7 shows the EIC of the M7 isomers of mAb2 for
the 2-AB (Fig. 7A) and 2-AA (Fig. 7B)-labeled glycans.
Four different isomers are observed for this high-mannose
glycan. The linkage could not be deduced with the reducing
end derivatization used. The selectivity of the two methods
is identical for the high-mannose structures; by comparison


























































Fig. 5 MS2 spectrum of the
2-AA-labeled SM5G1F glycan
from mAb3 at m/z 1088.4.
Singly charged B and Y ions
resulting from the [M + 2H]2+
ion are shown. B ions were
exclusively from the α-branch
containing a GlcNAc that is
able to carry a charge. Dissoci-













































Fig. 6 MS2 spectrum of the 2-
AA-labeled G3F N-glycan from
mAb3. The dissociated bonds
of the [M + 2H]2+ ion are
depicted and the assigned B and
Y ions are labeled in the spec-
trum. The glycan accounts
for <0.01 % of the glycans of
mAb3. Dissociation of two
bonds is indicated by a slash
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order of elution might have changed because the ratio of the
peak areas was inverted for the two labels (approx. 1.6 for 2-
AA peaks 3:4 and approx. 1.6 for 2-AB peaks 4:3).
G1F isomers are usually highly abundant structural iso-
mers on mAbs and IgG (Fig. 7E) with the terminal galactose
residue at the α1,3 or α1,6 branch [6]. So far, separation of
these two isomers has been achieved by use of HILIC and
porous graphitized carbon liquid chromatography only [24].
In Fig. 7 it is clearly apparent that the combination of 2-AA
as label and the RP chromatography conditions chosen is
capable of separating these isomers whereas the 2-AB RP
method is not. Figure 7C shows the EIC of the G1F 2-AB
glycan, which elutes as one peak because separation could
not be achieved during method development. Figure 7D
illustrates the selectivity of the 2-AA method toward the
complex N-glycans. From quantitative data obtained by
HILIC chromatography we could deduce that the first, larg-
er peak is that of the α1,6 isomer and the second, smaller
peak is that of the α1,3 isomer.
We also evaluated the performance of our 2-AA method
with more highly branched N-glycans with additional sialic
acids. Six N-glycan standards with two, three, and four
antennae were labeled. Each glycoform is present with
and without a core fucose. All antennae carry one terminal
N-acetylsialic acid. Overlays of the chromatograms, with the
appropriate glycan structure, are shown in Fig. 8. The acidic
N-glycans elute in accordance with the overall grouping
(Fig. 2) and the separation between fucosylated and non-
fucosylated glycans is obvious.
High sensitivity as a result of large injection volume
The possibility of using large injection volumes of aqueous
samples in RP LC enables detection and identification, by
fluorescence detection or mass spectrometry, of N-glycan
variants which occur only at very low levels. Compared
with HILIC, in which only few microliters of an aqueous
sample can be injected, this circumstance is of huge advan-
tage because the labeled and purified N-glycans are eluted in
600 μL H2O in the last step of our sample-preparation
procedure. The sample can be injected without any addi-
tional concentration steps. N-Glycans accounting for less
than 0.01 % of total mAb N-glycans, for example G3F
(shown in Fig. 6) can be easily detected and identified by
ion-trap MS, resulting in a high-sensitivity glycan map of
the analyzed mAb.
Fig. 7 EICs of four structural M7 isomers (A, B) and G1F
isomers (C, D) from mAb2. (A) EIC of 2-AB-labeled N-glycans.
(B) EIC for the 2-AA-labeled glycans. Although selectivity is
identical for the M7 isomers in both approaches, comparison of
the peak areas reveals the order of elution changed for peaks 3
and 4. Selectivity is different for the G1F isomers. The 2-AB-
labeled G1F elutes as one peak (C) whereas the 2-AA-labeled
glycans (D) are separated into the two isomers. The terminal
galactose residue (E) can be linked either to the α1,6 or the
α1,3 branch of the bi-antennary N-glycan
Fig. 8 Overlay of fluorescence chromatograms derived from six dif-
ferent 2-AA-labeled sialic N-glycan standards. The appropriate struc-
tures are depicted. The grouping into non-fucosylated (three peaks on
the left) and fucosylated (three peaks on the right) glycans is obvious
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Analysis of different glycosylated mAbs
We analyzed the glycosylation pattern of three different mAbs
by use of the 2-AA RP LC–MS method to demonstrate the
flexibility and versatility of the method for mAb N-glycan
characterization. The fluorescence chromatograms are shown
in Figs. 9, 10 and 11. These mAbs were chosen because of
their different glycan content. The N-glycosylation pattern
of mAb1 (Fig. 9) is indicative of the smallest amount of high-
mannose structures but the largest amount of non-fucosylated
complex glycans. Moreover it is the only mAb with both N-
acetylneuraminic acid and N-glycoylneuraminic acid. It
consists of 2 % high-mannose structures and <1 %
hybrid structures without core fucose, and 7 % are complex
structures lacking the core fucose. Hybrid and complex
N-glycans with α1,6 core fucose account for <1 % and
90%, respectively. Approximately 2 % of the N-glycans carry
a terminal sialic acid.
mAb2 (Fig. 10) has the highest amount of different
oligomannose glycans and carries no sialylation. High-
mannose structures account for 7 % of all glycans. Non-
fucosylated hybrids account for <1 % and non-fucosylated
Fig. 9 RP FLD chromatogram
obtained from mAb1 N-glycans
after labeling with 2-AA. Peaks
identified by MS and MS2 are
numbered, and are listed in
Table 1. The appropriate 2-AA
glycans are shown in Fig. 3.
The magnified view (small
window) of the chromatogram
shows the smaller peaks
Fig. 10 RP FLD chromatogram
obtained from mAb2 N-glycans
after labeling with 2-AA. Peaks
identified by MS and MS2 are
numbered, and are listed in
Table 1. The appropriate 2-AA
glycans are shown in Fig. 3. The
magnified view (small window)
of the chromatogram shows the
smaller peaks. Stacked number-
ing indicates co-elution of
N-glycans. Quantitative data
obtained from FLD and MS for
mAb2 are listed in Table 2
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complexes account for 2 % of the glycans. Hybrid and
complex glycoforms with core fucose account for 1 % and
90 %, respectively. Relative amounts of glycans obtained
from either fluorescence or MS results are listed, as
examples, in Table 2. FLD data were obtained by inte-
gration of the peaks. Quantification by MS was per-
formed by use of extracted ion chromatograms for the
appropriate glycans. In general, the comparison shows
there is good correlation between FLD and MS results,
demonstrating the accuracy of the methods. Co-eluting
structures 50, 52, 59, and 60 could be quantified indi-
vidually by MS. The differences between MS and FLD
detection for peaks 62 and 63 can be explained by the
overlapping of the two peaks. For FLD quantification
the peaks were split, resulting in a higher peak area for
peak 62, whereas for MS detection the peaks could be
quantified individually by use of their EICs. In the sum
the peak areas are equal. There are larger differences
between the EIC and FLD values for some glycan
species of minor abundance; these result from larger
relative integration errors of the EIC and FLD signals.
mAb3 (Fig. 11) has the most complex N-glycosylation
pattern of the antibodies analyzed. It is characterized by a
large amount of hybrid structures and by oligomannose and
several sialic acid moieties carrying glycans. The glycosyl-
ation consists of 5 % oligomannose structures and 5 % non-
fucosylated hybrid structures. Complex variants account for
4 % of all glycans. Fucosylated hybrid glycans account for
5 %. Complex fucosylated glycans account for 85 % and the
sialylation level is rather high at 5 % for this mAb. The
relative glycan composition of the three mAbs was calculated
by using the peak area from the fluorescence chromatogram of
the RP LC runs; for unresolved or coeluting glycans the EIC
was used for integration. The N-glycan structures assigned to
each numbered peak are illustrated in Fig. 3.
Qualification of the method
The method was qualified to demonstrate its robustness and
reliability. Sample preparation, including deglycosylation
by use of PNGaseF, N-glycan separation by ultrafiltration,
N-glycan labeling using 2-AB, and the gel filtration step to
Fig. 11 RP FLD
chromatogram obtained from
mAb3 N-glycans after labeling
with 2-AA. Peaks identified
by MS and MS2 are numbered,
and are listed in Table 1. The
appropriate 2-AA glycans are
shown in Fig. 3. The magnified
view (small window) of the
chromatogram shows the
smaller peaks. Stacked num-
bering indicates co-elution of
N-glycans
Table 2 Comparison of fluorescence and MS data of 2-AA-labeled mAb2. Relative amounts of glycans (%) derived from the fluorescence signal
(upper panel) and the MS data (lower panel) are listed for the appropriate peak number
Peak# 5 6 10 7 13 11 8 9 20 22 14 25 28 29
FLD 0.07 0.22 0.02 0.17 1.29 0.15 0.02 0.05 0.22 4.08 0.11 0.02 0.72 0.06
MS 0.08 0.22 0.03 0.15 1.12 0.26 0.07 0.08 0.27 4.37 0.14 0.03 0.66 0.17
Peak# 33 37 46 48 54 53 61 62 63 36 50 52 59 60
FLD 0.83 0.01 0.23 0.20 0.96 0.12 12.96 2.73 70.06 0.32 4.27
MS 1.20 0.10 0.05 0.08 0.79 0.08 12.95 5.29 67.43 0.26 0.15 0.18 2.42 1.37
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remove excess label is a standard company procedure which
has been reported elsewhere [23]. Reproducibility of fluo-
rescence labeling by 2-AAwas monitored by performing the
two labeling reactions in parallel and by comparing the rela-
tive amounts of glycans. Robustness and linearity were
assessed by testing different column batches and by analyzing
dilutions of analyte (e.g. mAb1 total peak area R2=0.9992),
respectively. Intra-assay precision was monitored by repeated
sample preparation and analysis by the same operator. For
example, for relative quantification of mAb2 glycans by fluo-
rescence coefficient of variation (%CV) values were calculat-
ed (e.g. peaks 22 (1.24 %) and 63 (1.17 %), and total glycan
area (5.42 %)).All HPLC and MS experiments were con-
ducted with qualified instruments.
Conclusion
This glycan-mapping method using RP HPLC of 2-AB or 2-
AA-labeled N-glycans in combination with fluorescence de-
tection and on-line ion-trap mass spectrometry enables high-
sensitivity and high-resolution N-glycan analysis. The 2-AA
method enables analysis of neutral and acidic N-glycans with
positive ESI–MS. Compared with the RP LC–MS of 2-AB-
labeled N-glycans more structural isomers can be separated in
a shorter analysis time. In particular, separation of the highly
abundant and isobaric G1F isomers was achieved. The 2-AA
chromatogram obtained from the mAb glycan standard
(Fig. 2) also contains more peaks and partially resolved peaks,
because of the greater selectivity and resolution of the method.
This selectivity of the reversed-phase chromatography in
combination with 2-AA labeling enables separation of a vari-
ety of structural isomers of different types of N-glycan and,
more important, separates the N-glycans into seven different
groups: oligomannose, hybrid, and complex without core
fucosylation, hybrid and complex with core fucosylation,
and two sialic acid-containing groups again with and without
the core fucose residues; this enables rapid screening of the
glycan composition. The ability to separate N-glycans with
multiple sialic acids and up to four antennae shows the versa-
tility of the method. Retention of 2-AA on the reversed phase
is better than that of 2-AB; this may result from the greater
hydrophobicity of the protonated carboxyl group of the 2-AA
label in the acidic mobile phase. The better retention and
separation results in sharper peaks and, because of the greater
sensitivity in fluorescence detection of 2-AA [19, 31], analysis
of rare glycan species becomes possible. In addition, focusing
of the analyte on the column leads to a more concentrated
sample entering the ionization chamber of the mass spectrom-
eter and enables efficient ionization and more sensitive MS
detection. Fragmentation of the, mostly, [M + 2H]2+ ions by
CID produces the mainly occurring B and Y ions, providing
information about the N-glycan structure. We observed good
ionization of the 2-AA-labeled N-glycans in positive ESI–MS,
and even for sialylated structures the MS signal was intense
and on-line MS2 data were obtained. Because of the high
resolution of the liquid chromatography and the sensitive MS
detection, the high complexity of mAb N-glycosylation can be
investigated in detail. The large injection volume even enables
detection and quantificationN-glycans of very low abundance.
Analysis of three mAbs with different glycosylation patterns
showed the flexibility of the method for mAb N-glycan char-
acterization. Furthermore, our data show that relative quantifi-
cation with FLD data is comparable with quantification byMS
for the labeled mAb N-glycans; this was somewhat expected,
because the molecular composition of the glycans is similar
and the masses are distributed over a relatively small range.
The low hydrophobicity of the labeled glycans, which enables
good separation, also makes MS quantification more accurate,
because the ACN content changes slowly and conditions in the
ionization chamber of the mass spectrometer during analyte
elution are almost identical. Co-eluting glycans could also be
quantified individually by use of MS data. For samples con-
taining N-glycans with a larger size distribution, however,
comparability must be evaluated individually.
To summarize, our 2-AA RP LC–MS approach can be
used as a robust method which is orthogonal to the widely
established HILIC of 2-AB glycans or MALDI MS of
labeled neutral and acidic N-glycans derived from mAbs
and other glycoproteins. In this work we demonstrated the
strength and versatility of RP LC with on-line MS detection
for analysis of N-glycosylation.
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